Literature DB >> 31398540

Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report.

Anne-Marie C Dingemans1, Lizza E L Hendriks2, Thierry Berghmans3, Antonin Levy4, Baktiar Hasan5, Corinne Faivre-Finn6, Matteo Giaj-Levra7, Niccolò Giaj-Levra8, Nicolas Girard9, Laurent Greillier10, Sylvie Lantuéjoul11, John Edwards12, Mary O'Brien13, Martin Reck14, Egbert F Smit15, Paul Van Schil16, Pieter E Postmus17, Sara Ramella18, Yolande Lievens19, Mina Gaga20, Nir Peled21, Giorgio V Scagliotti22, Suresh Senan23, Luiz Paz-Ares24, Matthias Guckenberger25, Fiona McDonald26, Simon Ekman27, Tanja Cufer28, Hester Gietema29, Maurizio Infante30, Rafal Dziadziuszko31, Solange Peters32, Ramon Rami Porta33, Johan Vansteenkiste34, Christophe Dooms34, Dirk de Ruysscher35, Benjamin Besse36, Silvia Novello22.   

Abstract

INTRODUCTION: Improved outcome has been shown in patients with synchronous oligometastatic (sOM) NSCLC when treated with radical intent. As a uniform definition of sOM NSCLC is lacking, we developed a definition and diagnostic criteria by a consensus process.
METHODS: A pan-European multidisciplinary consensus group was established. Consensus questions were built on the basis of current controversies, and definitions were extracted from a survey, cases and a systematic review. This statement was formulated during a consensus meeting.
RESULTS: It was determined that definition of sOM NSCLC is relevant when a radical treatment that may modify the disease course (leading to long-term disease control) is technically feasible for all tumor sites with acceptable toxicity. On the basis of the review, a maximum of five metastases and three organs was proposed. Mediastinal lymph node involvement was not counted as a metastatic site. Fludeoxyglucose F 18 positron emission tomography-computed tomography and brain imaging were considered mandatory. A dedicated liver magnetic resonance imaging scan was advised for a solitary liver metastasis, and thoracoscopy and biopsies of distant ipsilateral pleural sites were recommended for a solitary pleural metastasis. For mediastinal staging, fludeoxyglucose F 18 positron emission tomography-computed tomography was deemed the minimum requirement, with pathological confirmation recommended if this influences the treatment strategy. Biopsy of a solitary metastatic location was mandated unless the multidisciplinary team is of the opinion that the risks outweigh the benefits.
CONCLUSION: A multidisciplinary consensus statement on the definition and staging of sOM NSCLC has been formulated. This statement will help to standardize inclusion criteria in future clinical trials.
Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Consensus definition; Non–small cell lung cancer; Oligometastatic disease; Staging

Mesh:

Year:  2019        PMID: 31398540     DOI: 10.1016/j.jtho.2019.07.025

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  57 in total

1.  What is synchronous oligometastatic non-small cell lung cancer?

Authors:  Chan-Kyung Jane Cho; Balamurugan A Vellayappan; Emma M Dunne; Shankar Siva; Mitchell Liu; Alexander V Louie; Gerard G Hanna; Simon S Lo
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

2.  A first attempt to establish a definition of oligometastatic non-small cell lung cancer by a European consensus group.

Authors:  Koji Haratani; Masayuki Takeda; Kazuhiko Nakagawa
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

3.  Accelerating the development of therapeutic strategy for oligometastasis.

Authors:  Yoshihisa Shimada
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

4.  The Role of Local Treatment in Oligometastatic and Oligoprogressive Cancer.

Authors:  Jan Haussmann; Christiane Matuschek; Edwin Bölke; Klaus Orth; Pirus Ghadjar; Wilfried Budach
Journal:  Dtsch Arztebl Int       Date:  2019-12-13       Impact factor: 5.594

5.  Rurality, Stage-Stratified Use of Treatment Modalities, and Survival of Non-small Cell Lung Cancer.

Authors:  Meredith A Ray; Nicholas R Faris; Anna Derrick; Matthew P Smeltzer; Raymond U Osarogiagbon
Journal:  Chest       Date:  2020-05-06       Impact factor: 9.410

Review 6.  A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done.

Authors:  Lorenzo Belluomini; Alessandra Dodi; Alberto Caldart; Dzenete Kadrija; Marco Sposito; Miriam Casali; Giulia Sartori; Miriam Grazia Ferrara; Alice Avancini; Emilio Bria; Jessica Menis; Michele Milella; Sara Pilotto
Journal:  Transl Lung Cancer Res       Date:  2021-07

Review 7.  Radiation for Oligometastatic Lung Cancer in the Era of Immunotherapy: What Do We (Need to) Know?

Authors:  Stephanie T H Peeters; Evert J Van Limbergen; Lizza E L Hendriks; Dirk De Ruysscher
Journal:  Cancers (Basel)       Date:  2021-04-28       Impact factor: 6.639

Review 8.  Defining oligometastatic non-small cell lung cancer: concept versus biology, a literature review.

Authors:  Jill F Mentink; Marthe S Paats; Daphne W Dumoulin; Robin Cornelissen; Joris B W Elbers; Alexander P W M Maat; Jan H von der Thüsen; Anne-Marie C Dingemans
Journal:  Transl Lung Cancer Res       Date:  2021-07

9.  Complete disease remission in a TP53 and KRAS co-mutated brain oligometastatic lung cancer patient after immuno-chemotherapy and surgical resection: a case report.

Authors:  Shuai Zhu; Shikang Zhao; Qian Zhang; Shuo Li; Dian Ren; Fan Ren; Lingling Zu; Yanye Wang; Xi Lei; Ning Zhou; Tao Shi; Dongbo Xu; Gang Chen; Wan-Teck Lim; Raffaele Giusti; Abraham J Wu; Song Xu
Journal:  Transl Lung Cancer Res       Date:  2021-05

Review 10.  Oligometastatic non-small cell lung cancer: Current management.

Authors:  Alicia Román-Jobacho; María Hernández-Miguel; María Jesús García-Anaya; Jaime Gómez-Millán; J A Medina-Carmona; Ana Otero-Romero
Journal:  J Clin Transl Res       Date:  2021-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.